Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Poractant Alfa - Curosurf and SARS-COV-19 ARDS (Covid-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04502433
Recruitment Status : Recruiting
First Posted : August 6, 2020
Last Update Posted : January 20, 2021
Sponsor:
Information provided by (Responsible Party):
Chiesi Farmaceutici S.p.A.

Tracking Information
First Submitted Date  ICMJE August 3, 2020
First Posted Date  ICMJE August 6, 2020
Last Update Posted Date January 20, 2021
Actual Study Start Date  ICMJE January 6, 2021
Estimated Primary Completion Date July 31, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 5, 2020)
number of ventilator-free days [ Time Frame: up to 21 days ]
The primary outcome variable will be the number of ventilator-free days, defined as the number of days the patient is not receiving mechanical ventilation during the 21 days following randomisation.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: August 5, 2020)
  • Number of free days from invasive ventilation [ Time Frame: up to 21 days ]
  • Number of free days from non-invasive ventilation (NIV) [ Time Frame: up to 21 days ]
  • Change from baseline in PaO2/FiO2 ratio measured at 6 hours and 12 hours following administration of each dose in the treated group and at the similar timepoints in the control group [ Time Frame: 6, 12, 30, 36, 54 and 60 hours after randomisation ]
  • Change from baseline in PaO2/FiO2 ratio at additional timepoints [ Time Frame: every 24 hours after treatment/randomisation until the patient is discharged from the ICU . Up to 28 days ]
  • Length of ICU stay (days) [ Time Frame: up to 28 days ]
  • Mortality at Day 28 [ Time Frame: Day 28 ]
  • Change from baseline in ventilatory parameter (Tidal volume (TV)) [ Time Frame: up to 28 days ]
  • Delta Sequential Organ Failure Assessment (SOFA) Score [ Time Frame: up to 28 days ]
    min score 0 max score 24
  • Incidence of all the AEs, AEs related to poractant alfa (treated cohort) (ADRs), serious AEs (SAEs) and AEs leading to death [ Time Frame: up to 28 days ]
  • Change from baseline in blood gas analysis acid-base balance parameter (pH) [ Time Frame: up to 28 days ]
  • Percentage of patients with PaO2/ FiO2 improvement of >20% following administration of each dose in the treated group and at similar timepoints in the control group [ Time Frame: at 6 and 12 hours following administration each dose in the treated group and at similar timepoints in the control group = up to 60 hours after the randomization ]
  • Number of Extracorporeal Membrane Oxygenation (ECMO)-free days- (only for cohort 2 of patients in ECMO) [ Time Frame: 21 days after randomization ]
  • Change from baseline in FiO2 [ Time Frame: (6, 12, 30, 36, 54 and 60 hours after randomisation + every 24 hours after treatment/randomisation until the patient is discharged from the ICU = up to 28 days ]
  • Change from baseline in ventilatory parameter (respiratory rate (RR)) [ Time Frame: up to 28 days ]
  • Change from baseline in ventilatory parameter (dynamic compliance (Cdyn)) [ Time Frame: up to 28 days ]
  • Change from baseline in ventilatory parameter (static compliance (Cstat)) [ Time Frame: up to 28 days ]
  • Change from baseline in ventilatory parameter (positive end-expiratory pressure (PEEP) [ Time Frame: up to 28 days ]
  • Change from baseline in ventilatory parameter (peak inspiratory pressure (PIP)) [ Time Frame: up to 28 days ]
  • Change from baseline in ventilatory parameter (plateau pressure (Pplat)) [ Time Frame: up to 28 days ]
  • Change from baseline in blood gas analysis acid-base balance parameter (pCO2) [ Time Frame: up to 28 days ]
  • Change from baseline in blood gas analysis acid-base balance parameter (pO2) [ Time Frame: up to 28 days ]
  • Change from baseline in blood gas analysis acid-base balance parameter (HCO3) [ Time Frame: up to 28 days ]
  • Change from baseline in blood gas analysis acid-base balance parameter (lactate) [ Time Frame: up to 28 days ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Poractant Alfa - Curosurf and SARS-COV-19 ARDS (Covid-19)
Official Title  ICMJE Multicenter, Open-label, Randomised Trial to Assess the Efficacy and Tolerability of Poractant Alfa(Porcine Surfactant, Curosurf®) in Hospitalized Patients With SARS-COV-19 Acute Respiratory Distress Syndrome (ARDS)
Brief Summary The purpose of this Phase II -Proof of Concept study is to evaluate the efficacy and safety of poractant alfa (Curosurf®), administered by endotracheal (ET) instillation in adult hospitalized patients with SARS-COV-19 acute respiratory distress syndrome (ARDS)
Detailed Description

This is a UK multicentre, open-label, randomized phase II proof of concept study.

The efficacy and safety of poractant alfa will be evaluated in terms of ventilatory free days during the 21 days after randomization, in adult patients with ARDS due to SARS-COV-19 infection.

The same evaluation is planned in a separate cohort of patients under extracorporeal membrane oxygenation (vvECMO) in terms of ECMO free days during the 21 days after randomization.

Each patient randomized to the study treatment will receive three administrations of Curosurf ® with a 24 hours dosing interval.

The assessment collection will last until day 28 when the evaluation will occur at the ICU, or by phone call if the patient has been discharged before.

Seventy patients will be randomized in the study with a ratio 3:2 (i.e. 42 patients in the poractant alfa arm and 28 in the control arm). An additional exploratory cohort of 15 patients in ECMO will be randomised by 3 sites with a ratio 3:2 (i.e. 9 patients in the poractant alfa arm and 6 in the control arm).

The control arm population is treated as per Standard of Care (SoC).

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Seventy patients will be randomized in the study with a ratio 3:2 (i.e. 42 patients in the poractant alfa arm and 28 in the control arm). An additional exploratory cohort of 15 patients in ECMO will be randomized by 3 sites with a ratio 3:2 (i.e. 9 patients in the poractant alfa arm and 6 in the control arm).
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Acute Respiratory Distress Syndrome
Intervention  ICMJE Drug: CUROSURF® (poractant alfa)

Three administrations with a 24 hours dosing interval.

Each ET administration 1, 2, and 3 will consist of poractant alfa bolus:

30mg /kg (Lean Body Weight-LBW) = 0.375ml /kg LBW. Dilution with normal saline up to 2ml /kg LBW

Study Arms  ICMJE
  • No Intervention: Control cohort
    Approximately 28 patients will be included in this main control cohort. An additional exploratory cohort of 6 patients in ECMO will be enrolled by 3 sites. The above-mentioned control cohort population will continue receiving the SoC
  • Experimental: Poractant alfa treated cohort
    42 patients will be treated with CUROSURF® (poractant alfa). An additional exploratory cohort of 9 patients in ECMO will be randomised by 3 sites and treated with the poractant alfa
    Intervention: Drug: CUROSURF® (poractant alfa)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: August 5, 2020)
85
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE July 31, 2021
Estimated Primary Completion Date July 31, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Participants are eligible to be included in the study if the following criteria apply:

  1. Male or female ≥18 and ≤ 80 years of age
  2. Informed consent for participation in the study (refer to section 15 for detailed inform consent procedure)
  3. Positive 2019-nCoV rt-PCR before randomisation
  4. PaO2/FiO2 ratio < 150 mmHg
  5. Lung compliance ≤45 ml/cmH20
  6. Intubated and artificially ventilated less than 48 hours before the first poractant alfa administration

    Additional inclusion criterion for ECMO-cohort:

  7. Supported with vvECMO less than 48 hours before the first poractant alfa administration - for the ECMO-cohort substudy cohort only

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  1. Any contraindications to surfactant administration e.g., pulmonary hemorrhage and pneumothorax)
  2. Weight < 40kg
  3. Stage 4 severe chronic kidney disease (i.e., eGFR < 30)
  4. Pregnancy
  5. Administration of any nebulized surfactant in the 48 hours before the first poractant alfa administration
  6. Extracorporeal membrane oxygenation* * [Exclusion criterion NOT applicable for patients eligible for the ECMO-cohort]
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Chiesi Clinical trial Info +39 0521 2791 clinicaltrials_info@chiesi.com
Listed Location Countries  ICMJE United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04502433
Other Study ID Numbers  ICMJE CLI-050000-04
2020-002632-75 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Chiesi Farmaceutici S.p.A.
Study Sponsor  ICMJE Chiesi Farmaceutici S.p.A.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Clark Howard, Prof. /MD University College, London
PRS Account Chiesi Farmaceutici S.p.A.
Verification Date January 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP